Massive database study probes link between popular diabetes drugs and rare thyroid cancer

NCT ID NCT07713901

ENROLLING_BY_INVITATION Knowledge-focused Sponsor: Novo Nordisk A/S Source: ClinicalTrials.gov ↗

First seen Jul 20, 2026 · Last updated Jul 21, 2026 · Updated 1 time

Summary

This study uses health records from millions of people to see if GLP-1 receptor agonists (drugs for type 2 diabetes and weight loss) are linked to a higher risk of medullary thyroid carcinoma, a rare cancer. Researchers will compare how often this cancer occurs in people taking GLP-1 RAs versus those on other treatments. The goal is to provide clearer safety information about these widely used medications.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

What this could lead to: If the study finds no link, it could reassure millions of people using GLP-1 RAs for diabetes or weight management.
What could go wrong: This is an observational study, not a controlled trial, so it can only show associations, not cause and effect. The rare cancer is very uncommon, making it hard to draw firm conclusions.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for MEDULLARY THYROID CARCINOMA are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

Carcinoma, Medullary familial medullary thyroid carcinoma type 2 diabetes mellitus

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

MEDULLARY THYROID CARCINOMA

Contacts and locations

Show contact details

Locations

IQVIA

Parsippany, New Jersey, 07054, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.